DSP-Visulex (dexamethasone sodium phosphate ophthalmic) / Aciont - LARVOL DELTA

Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Non-Infectious Anterior Uveitis: A Randomized Phase I/II Clinical Trial. (PubMed, Curr Eye Res) - "The efficacy of the DSP-Visulex applications was comparable to the daily PA drops in the treatment of non-infectious anterior uveitis. Both 8% and 15% DSP-Visulex treatments were safe and well tolerated."

Clinical • Journal • P1/2 data • CNS Disorders • Complement-mediated Rare Disorders • Corneal Abrasion • Immunology • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain • Rare Diseases • Uveitis

Ocular Drug Distribution and Safety of a Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in Rabbit. (PubMed, J Ocul Pharmacol Ther) - "DSP can be administered safely and effectively into the rabbit eye with the Visulex system. Treatment duration and DSP concentration are important factors in achieving therapeutic levels. Repeat applications of DSP-Visulex are safe and well tolerated for weekly administrations over 4-12 weeks. DSP-Visulex has clinical potential for the noninvasive treatment of ocular diseases."

Clinical • Journal